Spread the loveYou’ve probably heard the buzz about GLP-1 drugs – the injectables like Ozempic and Wegovy that have reshaped ...
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
Morning Overview on MSN
Loneliness raises the odds of dying from a heart attack or stroke by about 30%
People who live with chronic loneliness or social isolation face roughly 30 percent higher odds of suffering a fatal heart ...
Morning Overview on MSN
Ozempic and Mounjaro may raise the odds of hair loss, a big study finds
Millions of adults taking GLP-1 receptor agonists such as Ozempic and Mounjaro for type 2 diabetes or weight loss now face a ...
Results shows disease control in more than 80 percent of patients and cancer shrinkage in nearly 20 percent, offering ...
(Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing ...
Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and ...
Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer, and the number of new cases is predicted ...
Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be ...
Making carbohydrate-derived drugs from naturally occurring sugars often requires chemists to temporarily shield the sugar’s ...
The field of pediatric clinical pharmacology faces persistent challenges in balancing therapeutic innovation with safety, particularly when treating ...
Because of its heterogenous presentation, Sjögren disease is commonly misdiagnosed, leading to delays in treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results